CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-NK 细胞疗法在癌症治疗中的进展与挑战
英文原题：Advancements and challenges in CAR-NK cell therapy for cancer treatment.
查看英文原题
Advancements and challenges in CAR-NK cell therapy for cancer treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体自然杀伤（CAR-NK）细胞疗法是一种新兴的癌症治疗方法，相较于 CAR-T 疗法具有优势，包括降低细胞因子释放综合征和移植物抗宿主病的风险。本综述重点阐述基因工程如何通过 CAR 表达增强NK 细胞的先天杀瘤能力。临床前和临床研究显示出有前景的抗肿瘤反应，但仍存在挑战，例如确保体内持久性、克服免疫抑制性肿瘤微环境以及解决生产制造方面的障碍。本文探讨了细胞因子支持、联合疗法和新型 CAR 设计等策略以提高疗效。未来方向包括个性化方法、新型抗原靶点和人工智能整合。CAR-NK 疗法作为癌症免疫治疗中一种安全、可扩展且有效的模式具有强大潜力。
展开英文摘要原文
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is an emerging cancer treatment offering advantages over CAR-T therapy, including reduced risks of cytokine release syndrome and graft-versus-host disease. This review highlights how genetic engineering enhances natural killer cells' innate tumor-killing abilities through CAR expression.
Preclinical and clinical studies show promising antitumor responses, yet challenges remain, such as ensuring in vivo persistence, overcoming the immunosuppressive tumor microenvironment, and addressing manufacturing hurdles.
Strategies such as cytokine support, combination therapies, and novel CAR designs are explored to improve efficacy. Future directions include personalized approaches, novel antigen targets, and artificial intelligence integration. CAR-NK therapy holds strong potential as a safe, scalable, and effective modality in cancer immunotherapy.
论文信息
- 作者
- Xu Z、Li Y、Zhou Y、Ye C、Kuang J、Yin C、Zhao D、Guo H
- 第一作者单位
- Department of Thoracic Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China; Ministry of Education, Key Laboratory of Surgery Critical Care and Life Support (Xi'an Jiaotong University), Xi'an, Shanxi 710061, China.China
- 通讯作者单位
- Department of Thoracic Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China; Ministry of Education, Key Laboratory of Surgery Critical Care and Life Support (Xi'an Jiaotong University), Xi'an, Shanxi 710061, China. Electronic address: liushiyuan@xjtu.edu.cn.China
- 文献类型
- 综述
- 期刊
- Trends in biotechnology2026 Sep
- 原文标识
- PubMed 41702798 · DOI 10.1016/j.tibtech.2025.12.020